P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia ; volume:5 ; number:4 ; day:29 ; month:11 ; year:2011 ; pages:169 ; date:12.2011
Artery research ; 5, Heft 4 (29.11.2011), 169, 12.2011
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Ershova, A. I.
Meshkov, A. N.
Rozhkova, T. A.
Rogoza, A. N.
Balakhonova, T. V.
Boytsov, S. A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1016/j.artres.2011.10.077
- URN
-
urn:nbn:de:101:1-2404291020488.615752934321
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ershova, A. I.
- Meshkov, A. N.
- Rozhkova, T. A.
- Rogoza, A. N.
- Balakhonova, T. V.
- Boytsov, S. A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
P76 Carotid Artery Disease in Patients with Newly Diagnosed, Untreated Familial Hypercholesterolemia
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study
Current causes of death in familial hypercholesterolemia
Familial hypercholesterolemia in very young myocardial infarction
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
P76 Carotid Artery Disease in Patients with Newly Diagnosed, Untreated Familial Hypercholesterolemia
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study
Current causes of death in familial hypercholesterolemia
Familial hypercholesterolemia in very young myocardial infarction
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
P76 Carotid Artery Disease in Patients with Newly Diagnosed, Untreated Familial Hypercholesterolemia
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study
Current causes of death in familial hypercholesterolemia